TNF and Parkinson disease: The administration of a PPARγ agonist, rosiglitazone, arrests degeneration in both striatum and SNpc by decreasing TNF-α production and modulating microglial polarization in MPTPp (MPTP + probenecid) progressive mouse model of PD (Carta et al., 2011; Pisanu et al., 2014).